Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials

References

• Laughlin-Tommaso SK, Stewart EA. Moving toward individualized medicine for uterine leiomyomas. Obstet Gynecol. 2018;132(4):1–7. doi: 10.1097/AOG.0000000000002785.
   PubMed Web of Science ®Google Scholar
• Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–107. doi: 10.1067/mob.2003.99.
   PubMed Web of Science ®Google Scholar
• Marsh EE, Al-Hendy A, Kappus D, et al. Burden, prevalence, and treatment of uterine fibroids: a survey of U.S. women. J Womens Health. 2018;27(11):1359–1367. doi: 10.1089/jwh.2018.7076.
   PubMed Web of Science ®Google Scholar
• Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157–178. doi: 10.1016/S1701-2163(15)30338-8.
   PubMed Web of Science ®Google Scholar
• Chiumente M, De Rosa M, Messori A, et al. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women. Clinicoecon Outcomes Res. 2017;9:525–535. doi: 10.2147/CEOR.S139335.
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Bernuit D, Gerlinger C, et al. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6. doi: 10.1186/1472-6874-12-6.
   PubMed Web of Science ®Google Scholar
• Williams ARW. Uterine fibroids – what’s new? F1000Res. 2017;6:2109. doi: 10.12688/f1000research.12172.1.
   PubMedGoogle Scholar
• Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: burden and unmet medical need. Semin Reprod Med. 2017;35(6):473–480. doi: 10.1055/s-0037-1607264.
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. Management of uterine fibroids. Comparative effectiveness review, no. 195. Rockville (MD): Agency for Healthcare Research and Quality (US) [Internet]; 2017 [cited 2021 Nov]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537742/
   Google Scholar
• Shon J, Zou P, Tran D, et al. Clinical pharmacology at the intersection of women’s health and regulation: drug development considerations for uterine fibroids. J Clin Pharmacol. 2020;60(Suppl. 2):S39–S48. doi: 10.1002/jcph.1736.
   PubMedGoogle Scholar
• Lewis TD, Malik M, Britten J, et al. A comprehensive review of the pharmacologic management of uterine leiomyoma. Biomed Res Int. 2018;2018:2414609. doi: 10.1155/2018/2414609.
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist. Fertil Steril. 2020;114(4):739–741. doi: 10.1016/j.fertnstert.2020.07.028.
   PubMed Web of Science ®Google Scholar
• Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167–174. doi: 10.1016/j.ejphar.2013.12.001.
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384(7):630–642. doi: 10.1056/NEJMoa2008283.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ryeqo (40 mg relugolix, 1 mg estradiol (as hemihydrate), and 0.5 mg norethisterone acetate). Summary of product characteristics; 2023 [cited 2023 Jul]. Available from: https://www.ema.europa.eu/en/documents/product-information/ryeqo-epar-product-information_en.pdf
   Google Scholar
• US Food and Drug Administration. Myfembree (relugolix, estradiol, norethindrone acetate) prescribing information; 2023 [updated 2023 Jul; cited Sep 2022]. Available from: https://www.myfembree.com/static/myfembree-prescribing-information.pdf
   Google Scholar
• Li J, Kang J, Hunsche E, et al. PIH57 the Bleeding and Pelvic Discomfort Scale: measuring patient-reported symptoms in uterine fibroids. Value Health. 2019;22:S637–S638. doi: 10.1016/j.jval.2019.09.1237.
   Web of Science ®Google Scholar
• Mäkinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252–255. doi: 10.1126/science.1208930.
   PubMed Web of Science ®Google Scholar
• Matsubara A, Sekine S, Yoshida M, et al. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology. 2013;62(4):657–661. doi: 10.1111/his.12039.
   PubMed Web of Science ®Google Scholar
• Halder SK, Laknaur A, Miller J, et al. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015;290(2):505–511. doi: 10.1007/s00438-014-0938-x.
   PubMed Web of Science ®Google Scholar
• Wang L, Zeng H, Wang Q, et al. MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs. Sci Adv. 2015;1(9):e1500463. doi: 10.1126/sciadv.1500463.
   PubMed Web of Science ®Google Scholar
• Baranov VS, Osinovskaya NS, Yarmolinskaya MI. Pathogenomics of uterine fibroids development. Int J Mol Sci. 2019;20(24):6151. doi: 10.3390/ijms20246151.
   PubMed Web of Science ®Google Scholar
• Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine fibroids: from menarche to menopause. Clin Obstet Gynecol. 2016;59(1):2–24. doi: 10.1097/GRF.0000000000000164.
   PubMed Web of Science ®Google Scholar
• Catherino WH, Eltoukhi HM, Al-Hendy A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med. 2013;31(5):370–379. doi: 10.1055/s-0033-1348896.
   PubMed Web of Science ®Google Scholar
• Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165–173.e4. doi: 10.1016/j.fertnstert.2015.09.032.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409–420. doi: 10.1056/NEJMoa1103182.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421–432. doi: 10.1056/NEJMoa1103180.
   PubMed Web of Science ®Google Scholar
• Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565–1573. doi: 10.1016/j.fertnstert.2014.02.008.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133(3):423–433. doi: 10.1097/AOG.0000000000003141.
   PubMed Web of Science ®Google Scholar
• Hoshiai H, Seki Y, Kusumoto T, et al. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial. BMC Womens Health. 2021;21(1):375. doi: 10.1186/s12905-021-01475-2.
   PubMed Web of Science ®Google Scholar
• Piecak K, Milart P, Woźniakowska E, et al. Ulipristal acetate as a treatment option for uterine fibroids. Prz Menopauzalny. 2017;16(4):133–136.
   PubMedGoogle Scholar
• European Medicines Agency. Ulipristal acetate (Esmya). Summary of product characteristics; 2023 [updated 2023 Jul; cited Aug 2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/esmya-epar-product-information_en.pdf
   Google Scholar
• US Food and Drug Administration. Oriahnn (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) prescribing information; 2023 [updated 2023 Jul; cited 2021 Oct]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213388s000lbl.pdf
   Google Scholar
• Pohl O, Marchand L, Fawkes N, et al. Gonadotropin-releasing hormone receptor antagonist mono- and combination therapy with estradiol/norethindrone acetate add-back: pharmacodynamics and safety of OBE2109. J Clin Endocrinol Metab. 2018;103(2):497–504. doi: 10.1210/jc.2017-01875.
   PubMed Web of Science ®Google Scholar
• Stewart EA, Taylor HS, Taylor RN, et al. Efficacy and safety of linzagolix (lgx) for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids (UF): results from two phase 3 randomized clinical trials. Fertil Steril. 2020;114(3):e527. doi: 10.1016/j.fertnstert.2020.09.016.
   Web of Science ®Google Scholar
• European Medicines Agency. Linzagolix choline (Yselty). Summary of product characteristics; 2022 [cited 2023 Jul]. Available from: https://www.ema.europa.eu/en/documents/product-information/yselty-epar-product-information_en.pdf
   Google Scholar
• Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Long-term relugolix combination therapy for symptomatic uterine leiomyomas. Obstet Gynecol. 2022;140(6):920–930. doi: 10.1097/AOG.0000000000004988.
   PubMed Web of Science ®Google Scholar